Valproic acid affects the engraftment of TPO-expanded cord blood cells in NOD/SCID mice

Experimental Cell Research

Volumn 318, Issue 4, 2012, Pages 400-407

  Vulcano, Francesca ^a   Milazzo, Luisa ^b   Ciccarelli, Carmela ^b   Barca, Alessandra ^a   Agostini, Francesco ^c   Altieri, Ilaria ^a   Macioce, Giampiero ^a   Di Virgilio, Antonio ^a   Screnci, Maria ^d   De Felice, Lidia ^c   Giampaolo, Adele ^a   Hassan, Hamisa Jane ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^d POLICLINICO UMBERTO I   (Italy)

Author keywords

Cord blood transplantation; Hematopoietic progenitor cells; Hematopoietic stem cells; NOD SCID mice; Valproic acid

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN D3; THROMBOPOIETIN; TRANSCRIPTION FACTOR GATA 1; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD34 SELECTION; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL EXPANSION; CELL FRACTIONATION; CELL GROWTH; CELL LINEAGE; CELL POPULATION; CELL PROLIFERATION; CHIMERA; CLONOGENESIS; CONTROLLED STUDY; ENGRAFTMENT; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SCID MOUSE; UMBILICAL CORD BLOOD;

MUS;

EID: 84856098759     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.11.012     Document Type: Article

References (25)

1. Broxmeyer H.E. Biology of cord blood cells and future prospects for enhanced clinical benefit. Cytotherapy 2005, 7:209-218.
2. Shpall E.J., Quinones R., Giller R., Zeng C., Baron A.E., Jones R.B., Bearman S.I., Nieto Y., Freed B., Madinger N., Hogan C.J., Slat-Vasquez V., Russell P., Blunk B., Schissel D., Hild E., Malcolm J., Ward W., McNiece I.K. Transplantation of ex vivo expanded cord blood. Biol. Blood Marrow Transplant. 2002, 8:368-376.
3. Jaroscak J., Goltry K., Smith A., Waters-Pick B., Martin P.L., Driscoll T.A., Howrey R., Chao N., Douville J., Burhop S., Fu P., Kurtzberg J. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell system. Blood 2003, 101:5061-5067.
4. Kaushansky K., Drachman J.G. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene 2002, 21:3359-3367.
5. Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Ann. N. Y. Acad. Sci. 2005, 1044:139-141.
6. Ramsfjell V., Borge O.J., Veiby O.P., Cardier J., Murphy M.J., Lyman S.D., Lok S., Jacobsen S.E. Thrombopoietin, but not erythropoietin, directly stimulates multilineage growth of primitive murine bone marrow progenitor cells in synergy with early acting cytokines: distinct interactions with the ligands for c-kit and FLT3. Blood 1996, 88:4481-4492.
7. Borge O.J., Ramsfjell V., Cui L., Jacobsen S.E. Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34+CD38- bone marrow cells with multilineage potential at the single-cell level: key role of thrombopoietin. Blood 1997, 90:2282-2292.
8. Ramsfjell V., Borge O.J., Cui L., Jacobsen S.E. Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+ CD38-) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3, and inhibitory effects of TGF-beta and TNF-alpha. J. Immunol. 1997, 158:5169-5177.
9. Mattia G., Milazzo L., Vulcano F., Pascuccio M., Macioce G., Hassan H.J., Giampaolo A. Long-term platelet production assessed in NOD/SCID mice injected with cord blood CD34+ cells, thrombopoietin-amplified in clinical grade serum-free culture. Exp. Hematol. 2008, 36:244-252.
10. Ishikawa F., Livingston A.G., Minamiguchi H., Wingard J.R., Ogawa M. Human cord blood long-term engrafting cells are CD34+ CD38- Leukemia 2003, 17:960-964.
11. Kuendgen A., Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007, 110:943-954.
12. Bokelmann I., Mahlknecht U. Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol. Med. 2008, 14:20-27.
13. Soriano A.O., Yang H., Faderl S., Estrov Z., Giles F., Ravandi F., Cortes J., Wierda W.G., Ouzounian S., Quezada A., Pierce S., Estey E.H., Issa J.P., Kantarjian H.M., Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110:2302-2308.
14. Bug G., Gul H., Schwarz K., Pfeifer H., Kampfmann M., Zheng X., Beissert T., Boehrer S., Hoelzer D., Ottmann O.G., Ruthardt M. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res. 2005, 65:2537-2541.
15. De Felice L., Tatarelli C., Mascolo M.G., Gregorj C., Agostini F., Fiorini R., Gelmetti V., Pascale S., Padula F., Petrucci M.T., Arcese W., Nervi C. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res. 2005, 65:1505-1513.
16. Bartels M., Geest C.R., Bierings M., Buitenhuis M., Coffer P.J. Histone deacetylase inhibition modulates cell fate decisions during myeloid differentiation. Haematologica 2010, 95:1052-1060.
17. Seet L.F., Teng E., Lai Y.S., Laning J., Kraus M., Wnendt S., Merchav S., Chan S.L. Valproic acid enhances the engraftability of human umbilical cord blood hematopoietic stem cells expanded under serum-free conditions. Eur. J. Haematol. 2009, 82:124-132.
18. Liu B., Ohishi K., Yamamura K., Suzuki K., Monma F., Ino K., Nishii K., Masuya M., Sekine T., Heike Y., Takaue Y., Katayama N. A potential activity of valproic acid in the stimulation of interleukin-3-mediated megakaryopoiesis and erythropoiesis. Exp. Hematol. 2010, 38:685-695.
19. Mattia G., Vulcano F., Milazzo L., Barca A., Macioce G., Giampaolo A., Hassan H.J. Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release. Blood 2002, 99:888-897.
20. Burba I., Colombo G.I., Staszewsky L.I., De Simone M., Devanna P., Nanni S., Avitabile D., Molla F., Cosentino S., Russo I., De Angelis N., Soldo A., Biondi A., Gambini E., Gaetano C., Farsetti A., Pompilio G., Latini R., Capogrossi M.C., Pesce M. Histone deacetylase inhibition enhances self renewal and cardioprotection by human cord blood-derived CD34 cells. PLoS One 2011, 6:e22158.
21. Tipping A.J., Pina C., Castor A., Hong D., Rodrigues N.P., Lazzari L., May G.E., Jacobsen S.E., Enver T. High GATA-2 expression inhibits human hematopoietic stem and progenitor cell function by effects on cell cycle. Blood 2009, 113:2661-2672.
22. Bresnick E.H., Lee H.Y., Fujiwara T., Johnson K.D., Keles S. GATA switches as developmental drivers. J. Biol. Chem. 2010, 285:31087-31093.
23. Shima H., Takubo K., Tago N., Iwasaki H., Arai F., Takahashi T., Suda T. Acquisition of G state by CD34-positive cord blood cells after bone marrow transplantation. Exp. Hematol. 2010, 38:1231-1240.
24. Peled A., Petit I., Kollet O., Magid M., Ponomaryov T., Byk T., Nagler A., Ben-Hur H., Many A., Shultz L., Lider O., Alon R., Zipori D., Lapidot T. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283:845-848.
25. Whetton A.D., Graham G.J. Homing and mobilization in the stem cell niche. Trends Cell Biol. 1999, 9:233-238.